Bayer's Weinand On Broadening Value-Based Pricing Views

Bayer's pharma head Dieter Weinand talks about his biggest issues with current value-based pricing assessments for new drugs and how companion diagnostics will pave the way to easier pricing of oncology therapies.

IV1703_Medicine Gets Personal_1200x675
Weinand says industry is on the cusp of a scientific revolution • Source: Shutterstock

Bayer AG's head of pharma Dieter Weinand has warned the pharma industry it should act now to help broaden thinking and remove silos related to value-based assessments for new drugs, if it wants to unlock the next scientific revolution arising from breakthroughs like CRISPR gene editing.

"We are on the cusp of the next scientific revolution and we need to figure out how, comprehensively and long-term,...

More from Drug Pricing

More from Scrip